KRYS Krystal Biotech Inc: Total Company Value-to-Revenue Ratio

Krystal Biotech, Inc. (KRYS) has developed an innovative platform for the first skin gene therapy, capturing the niche for treating epidermolysis bullosa. The business model is based on massive scientific investments followed by a sharp reduction in production costs. The monopoly status of the drug Vyjuvek ensures lifelong patient loyalty. The price-to-sales multiple visualizes market expectations, where 17989.83 captures the current value of the indicator.
Financial and market metric breakdowns for Krystal Corp (KRYS)

The explosive sales growth of Krystal Biotech, Inc. (KRYS) revolutionary gene therapy necessitates a business valuation that accounts for net debt and cash. This indicator compares total enterprise value to annual revenue, allowing investors to distinguish fundamental undervaluation from stagnation, as clearly illustrated by the long-term EV/Revenue chart.